Literature DB >> 16116193

Expansion of functional endogenous antigen-specific CD4+CD25+ regulatory T cells from nonobese diabetic mice.

Emma L Masteller1, Matthew R Warner, Qizhi Tang, Kristin V Tarbell, Hugh McDevitt, Jeffrey A Bluestone.   

Abstract

CD4+CD25+Foxp3+ regulatory T cells (T(reg)) are critical for controlling autoimmunity. Evidence suggests that T(reg) development, peripheral maintenance, and suppressive function are dependent on Ag specificity. However, there is little direct evidence that the T(reg) responsible for controlling autoimmunity in NOD mice or other natural settings are Ag specific. In fact, some investigators have argued that polyclonal Ag-nonspecific T(reg) are efficient regulators of immunity. Thus, the goal of this study was to identify, expand, and characterize islet Ag-specific T(reg) in NOD mice. Ag-specific T(reg) from NOD mice were efficiently expanded in vitro using IL-2 and beads coated with recombinant islet peptide mimic-MHC class II and anti-CD28 mAb. The expanded Ag-specific T(reg) expressed prototypic surface markers and cytokines. Although activated in an Ag-specific fashion, the expanded T(reg) were capable of bystander suppression both in vitro and in vivo. Importantly, the islet peptide mimic-specific T(reg) were more efficient than polyclonal T(reg) in suppressing autoimmune diabetes. These results provide a direct demonstration of the presence of autoantigen-specific T(reg) in the natural setting that can be applied as therapeutics for organ-specific autoimmunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16116193     DOI: 10.4049/jimmunol.175.5.3053

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  78 in total

1.  Comparative study of regulatory T cells expanded ex vivo from cord blood and adult peripheral blood.

Authors:  Huahua Fan; Jie Yang; Jun Hao; Yana Ren; Liang Chen; Guiping Li; Rufeng Xie; Yiming Yang; Feng Gao; Mingyao Liu
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

2.  Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly.

Authors:  Anandharaman Veerapathran; Joseph Pidala; Francisca Beato; Xue-Zhong Yu; Claudio Anasetti
Journal:  Blood       Date:  2011-09-23       Impact factor: 22.113

Review 3.  Genetics, pathogenesis and clinical interventions in type 1 diabetes.

Authors:  Jeffrey A Bluestone; Kevan Herold; George Eisenbarth
Journal:  Nature       Date:  2010-04-29       Impact factor: 49.962

4.  Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9-23 epitope and involves functional epitope spreading.

Authors:  Suchitra Prasad; Adam P Kohm; Jeffrey S McMahon; Xunrong Luo; Stephen D Miller
Journal:  J Autoimmun       Date:  2012-05-28       Impact factor: 7.094

Review 5.  Special regulatory T-cell review: Suppressors regulated but unsuppressed.

Authors:  Judith A Kapp
Journal:  Immunology       Date:  2008-01       Impact factor: 7.397

6.  Heat-shock proteins: inflammatory versus regulatory attributes.

Authors:  Verônica Coelho; Femke Broere; Robert J Binder; Yehuda Shoenfeld; Kamal D Moudgil
Journal:  Cell Stress Chaperones       Date:  2008-02-28       Impact factor: 3.667

Review 7.  The IL-2/IL-2R system: from basic science to therapeutic applications to enhance immune regulation.

Authors:  Allison L Bayer; Alberto Pugliese; Thomas R Malek
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 8.  Can antigen-specific regulatory T cells protect against graft versus host disease and spare anti-malignancy alloresponse?

Authors:  Joseph Pidala; Claudio Anasetti
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

Review 9.  Next-generation regulatory T cell therapy.

Authors:  Leonardo M R Ferreira; Yannick D Muller; Jeffrey A Bluestone; Qizhi Tang
Journal:  Nat Rev Drug Discov       Date:  2019-09-20       Impact factor: 84.694

Review 10.  Pharmacologic targeting of regulatory T cells for solid organ transplantation: current and future prospects.

Authors:  Kassem Safa; Sindhu Chandran; David Wojciechowski
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.